1. Staffs and Students (April, 2009)

Professor Nobuyuki MIYASAKA
Masayoshi HARIGAI

Associate Professor Hitoshi KOHSAKA, Tetsuo KUBOTA,
Ryuji KOIKE, Toshihiro NANKI

Junior Associate Professor Kazuki TAKADA, Hideyuki IWAI
Assistant Professor Shinya HIRATA, Fumitaka MIZOGUCHI,
Michi TANAKA, Yoshinori NONOMURA

Research Nurse Shoko KAWASE
Graduate Student Akito TAKAMURA, Kaori WATANABE,
Kayoko KANEKO, Masayasu TOYOMOTO,
Naoko OKIYAMA, Ryoko SAKAI,
Yoshishige MIYABE, Chie MIYABE,
Akiko SUZUKI
Research Student Yousuke MURAKAMI
Resident Naoki KIMURA, Hisanori HASEGAWA,
Tadashi HOSOYA, Hayato YAMAZAKI,
Tomoko TAKIZAWA, Kenshi TAKENAKA,
Yoko NAKAZATO, Shin FUKUDA,
Yusuke MATSUO, Waka YOKOYAMA

2. Purpose of Education

We have provided medical students and graduates with the opportunity to obtain the ability to identify important clinical problems and to solve them by clinical reasoning through their active participation into the diagnosis and management of various rheumatic diseases.

3. Research Subjects

Following studies have been extensively carried out in our laboratory with various biochemical, immunological, molecular biological and statistical techniques:

2) Investigation of mechanism and development of new therapeutics for polymyositis.
3) The pathological role of chemokines/chemokine receptors in autoimmune diseases, including rheumatoid arthritis, polymyositis and scleroderma, for understanding their mechanisms and development of new therapeutics.
4) Investigation of role of BAFF/BLyS and Toll-like receptor in SLE.
5) Establishment of evidence-based treatment of rheumatic diseases.

4. Clinical Services

We have provided care to a large number of patients with diverse rheumatic diseases with 24,033 clinic visits and 299 hospital admissions in 2009. We have aimed to practice evidence-based medicine and to provide care that is in accordance with the global standard. We have contributed to the development of potential new drugs and treatments through participation into industry- as well as investigator-initiated clinical trials for chemical and biological agents. We have also contributed to the refinement of the care of rheumatoid arthritis patients through the conduct of various pharmacovigilance studies.

5. Publications

Original Article

Bioregulation (SATORI) : significantly reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19:12-19, 2009


20. Okiyama N, Sugihara T, Iwakura Y, Yokozeke H, Miyasaka N, Kohsaka H. Therapeutic effects of IL-6 blockade on a murine model of polymyositis that does not require IL-17A. Arthritis Rheum. 60 (8):2505-2512, 2009

Am80, on T helper cell development and antibody production in murine collagen-induced arthritis. Mod Rheumatol. 2009 Dec 29. [Epub ahead of print]


